Table 3 Summary of the patients’ therapies and follow-up results
Pat. no. | 177Lu- DOTATOC/ DOTATATE | Therapeutic activity (GBq) | Whole body residence time (h) | Maximum voxel activity (kBq)# | Lifetime in Tumor (h)§ | Maximum absorbed voxel dose (Gy) | Gy/GBq | EBRT target dose (Gy) | No. of fractions used for EBRT dose delivery | Change of EBRT dose due to PRRT (Gy) | Follow-up MR | Follow–up symptoms |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | DOTATOC | 7.0 | 39.3 | 71 | 72.4 | 4.0 | 0.57 | 60 | 30 | 0 | No change | Improvement of pituitary insufficiency,decreased vision unchanged |
2 | DOTATOC | 7.3 | 19.1 | 277 | 29.7 | 6.6 | 0.90 | 48.6 | 27 | −7 | No change | Retroorbital pressure fully resolved |
3 | DOTATOC | 7.5 | 25.7 | NA | 60.1 | 4.0* | 0.53 | 50 | 28 | −4 | No change | Cranial nerve palsy fully resolved |
4 | DOTATOC | 7.2 | 14.7 | 3 | 94.2 | 0.2 | 0.03 | 54 | 30 | 0 | Complete remission | Exophthalmus fully resolved |
5 | DOTATOC | 7.6 | 17.1 | 191 | 44.0 | 6.7 | 0.88 | 54 | 30 | 0 | No change | Partial loss of vision, decresed general performance constant |
6 | DOTATOC | 7.9 | 22.1 | 539 | 52.4 | 22.3 | 2.82 | 42 | 22 | −11 | No change | Headache, hypesthesia improved |
7 | DOTATATE | 7.9 | 27.2 | 557 | 68.2 | 30.7 | 3.89 | 60 | 30 | 0 | No change | Hemiparesis unchanged |
8 | DOTATATE | 7.2 | 26.6 | 124 | 74.6 | 7.2 | 1.00 | 40 | 20 | 0 | No change | Paresis left leg unchanged |
9 | DOTATATE | 7.3 | 32.3 | 305 | 69.6 | 16.6 | 2.27 | 54 | 30 | 0 | Partial remission | Epilepsy, tremor worsened, new hearing problems, resolved to pretherapeutic state after 2 months |
10 | DOTATATE | 7.4 | 32.5 | 161 | 64.8 | 8.2 | 1.11 | 52 | 20 | −6 | No change | Dizziness, ptosis constant |